Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios D Anastasilakis

Showing results (101-110 of 156) with videos related to

Pageof 16
Sort By:
JBMR Plus|April 20, 2026
Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patientsMaria P Yavropoulou, Maria-Evangelia Koloutsou, Polyxeni Delaporta, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
European Journal of Endocrinology|June 28, 2024
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, et al.
American Journal of Hematology|April 19, 2023
Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Sofia N Chatziioannou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Clinical Endocrinology|July 16, 2008
No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trialAthanasios D Anastasilakis, Dimirtios G Goulis, Stergios A Polyzos, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|April 21, 2011
Oxidized low-density lipoprotein and adiponectin levels in pregnancyKali Makedou, Anargyros Kourtis, Athina Gkiomisi, et al.
Bone|July 13, 2019
Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue SocietyAthanasios D Anastasilakis, Elena Tsourdi, Polyzois Makras, et al.
Pageof 16

Showing results (101-110 of 156) with videos related to

Sort By:
Pageof 16
JBMR Plus|April 20, 2026
Romosozumab for the treatment of thalassemia-associated osteoporosis in two female patientsMaria P Yavropoulou, Maria-Evangelia Koloutsou, Polyxeni Delaporta, et al.
Journal of Bone and Mineral Metabolism|June 10, 2015
Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver diseaseStergios A Polyzos, Athanasios D Anastasilakis, Jannis Kountouras, et al.
European Journal of Endocrinology|June 28, 2024
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?Athanasios D Anastasilakis, Maria P Yavropoulou, Andrea Palermo, et al.
American Journal of Hematology|April 19, 2023
Efficacy of denosumab monotherapy among adults with Langerhans cell histiocytosis: A prospective clinical trialPolyzois Makras, Maria P Yavropoulou, Sofia N Chatziioannou, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosisPolyzois Makras, Stergios A Polyzos, Athanasios D Anastasilakis, et al.
Clinical Endocrinology|July 16, 2008
No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trialAthanasios D Anastasilakis, Dimirtios G Goulis, Stergios A Polyzos, et al.
Frontiers in Endocrinology|March 16, 2026
Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic miceVagelis Rinotas, Eleftheria-Dimitra Ntouskou, Melina Dragolia, et al.
Metabolism: Clinical and Experimental|July 23, 2015
Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markersAthanasios D Anastasilakis, Stergios A Polyzos, Zoe A Efstathiadou, et al.
Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology|April 21, 2011
Oxidized low-density lipoprotein and adiponectin levels in pregnancyKali Makedou, Anargyros Kourtis, Athina Gkiomisi, et al.
Bone|July 13, 2019
Bone disease following solid organ transplantation: A narrative review and recommendations for management from The European Calcified Tissue SocietyAthanasios D Anastasilakis, Elena Tsourdi, Polyzois Makras, et al.
Pageof 16